Nonsmall Cell Lung Cancer clinical trials

Explore recruiting nonsmall cell lung cancer clinical trials.

Recruiting nonsmall cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nonsmall Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b/2 Open-Label, Multicenter Study of RMC-6236 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B

Spain, France, Italy, Netherlands, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2-overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer. (DESTINY-Lung06)

France, Belgium, Germany, Portugal, Italy, Greece +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI PD (L)1 THERAPY AND CHEMOTHERAPY (COSTAR LUNG)

Belgium, France, Greece, Italy, Finland, Netherlands +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

Nonsmall Cell Lung Cancer trials by city

Nonsmall Cell Lung Cancer in Toronto Nonsmall Cell Lung Cancer in Vancouver Nonsmall Cell Lung Cancer in Montreal Nonsmall Cell Lung Cancer in Calgary Nonsmall Cell Lung Cancer in Edmonton Nonsmall Cell Lung Cancer in Ottawa Nonsmall Cell Lung Cancer in Winnipeg Nonsmall Cell Lung Cancer in Quebec City Nonsmall Cell Lung Cancer in Hamilton Nonsmall Cell Lung Cancer in Kitchener Nonsmall Cell Lung Cancer in London Nonsmall Cell Lung Cancer in Halifax Nonsmall Cell Lung Cancer in New York Nonsmall Cell Lung Cancer in Los Angeles Nonsmall Cell Lung Cancer in Chicago Nonsmall Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease